ERBB2 and cholangiocarcinoma: Recent studies demonstrate the efficacy of FGFR inhibitors in cholangiocarcinoma patients [32] and could be an option for p53+/anti-HER2 refractory patients; however, this should be further evaluated in clinical trials.